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Abstract 21 
 22 
Given the proportion of individuals with resistance to, and poor compliance or tolerance 23 
of, anti-hypertensive medication new drugs to treat this syndrome are required 24 
urgently. We show that peripheral chemoreceptors generate aberrant signalling 25 
contributing to high blood pressure in hypertension and thus reveal a novel target. We 26 
discovered that P2x3 receptor mRNA expression was up regulated substantially in 27 
chemoreceptive petrosal sensory neurones in hypertensive rats. These neurones 28 
generated both tonic drive and hyperreflexia in hypertensive (but not normotensive 29 
rats), and both phenomena were normalised by blockade of P2X3 receptors. 30 
Antagonism of P2X3 receptors also reduced arterial pressure and basal sympathetic 31 
activity and normalised carotid body hyperreflexia in conscious hypertensive rats; no 32 
effect was observed in normotensive rats. These preclinical data support the P2X3 33 
receptor as a putative novel target for controlling human hypertension, a notion 34 
supported by our evidence of both P2X3 receptor expression in hypertensive human 35 
carotid body and the revelation of its hyperactivity. 36 
 37 
 38 
 39 
 40 
  41 
42 
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Introduction 43 
One third of the human population is hypertensive. In the USA, despite 75% of 44 
individuals using anti-hypertensive medication only 53% (~41 million) have blood 45 
pressure controlled1.  This may, in part, reflect the significant drug adherence problem 46 
due to the asymptomatic nature of hypertension and the poorly tolerated side-effects of 47 
current medication. Significant savings in healthcare costs are predicted if blood 48 
pressure was reduced to <140/90 mm Hg2. The clear evidence that a 10 mmHg rise in 49 
diastolic BP >115/75 mm Hg doubles the risk of death from cardiovascular disease in 50 
adults over 40 years3. Further, at least 8% of an estimated 900 million hypertensive 51 
humans worldwide4 currently have developed drug-resistance5,6. Categorically, there 52 
remains an unmet clinical need for controlling blood pressure. 53 
 54 
Aliskiren, a renin inhibitor, was the last anti-hypertensive drug introduced in 2007. This 55 
was the first new drug for thirteen years, yet its efficacy beyond the existing renin-56 
angiotensin–aldosterone enzyme inhibitors and receptor blockers is questionable, and 57 
associated adverse effects question its long-term benefit-harm relationship7. The 58 
paucity of novel pharmacological anti-hypertensives has led to a series of device based 59 
interventional studies including renal denervation8, stimulation of carotid 60 
baroreceptors9, deep brain stimulation10 and arterial venous anastomosis11,12. Here, we 61 
introduce a novel mechanistic approach using a highly selective small molecule 62 
antagonist, and provide the pre-clinical and clinical data that justifies its use in a future 63 
clinical trial in hypertension. 64 
 65 
Currently the carotid body is being considered as a novel therapeutic target for 66 
cardiovascular disease: (i) the carotid body chemoreflex-evoked sympathoexcitatory 67 
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response is potentiated in both a pre-clinical model of hypertension - the spontaneously 68 
hypertensive (SH) rat - and humans with hypertension13-18; (ii) denervation of the 69 
carotid body is evidently an effective way to control both the development and 70 
maintenance of high blood pressure in the SH rat19,20. We concluded that in conditions 71 
of hypertension the carotid body chemoreceptors generate aberrant excitatory tone 72 
driving up sympathetic activity and causing high blood pressure14,21. We found that by 73 
switching off this carotid body tone using either hyperoxia or nerve section to 74 
disconnect the carotid body from the brain, arterial pressure and sympathetic activity 75 
were reduced in SH rats, but were unaffected in a normotensive strain14. In 76 
hypertensive human, hyperoxia lowered sympathetic activity18 and carotid body 77 
resection can reduce arterial pressure22. Thus, the animal and human data support the 78 
presence of aberrant carotid body discharge contributing to hypertension. Although the 79 
mechanistic basis for the carotid body aberrant tone is unknown, it may be pivotal for 80 
refining new pharmacological anti-hypertensive approaches as we propose here. 81 
 82 
It is acknowledged that a plethora of mechanisms governs carotid body signalling23-27. 83 
We have considered in our current investigations the ATP gated ion channels (called 84 
purinergic P2X receptors), specifically the C-fiber localised P2X3 receptor subtypes, 85 
which are commonly associated with afferent sensitisation,  and that apparently may 86 
contribute to hyperreflexic disease states in a variety of organs28,29. ATP is one of a 87 
number of transmitters involved in the transduction process of hypoxia in the carotid 88 
body30-35. P2X3 receptor expression is present in both carotid bodies and petrosal 89 
ganglia neurones of normotensive rats36.  Moreover, combined P2X2 and P2X3 subunit 90 
deletion reduced the ventilatory response to hypoxia in mice37.  We hypothesised that 91 
P2X3 receptors contribute to both the chemo-hyper reflexia and aberrant discharge of 92 
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carotid body activity in hypertension and predict that their blockade would cause an 93 
anti-hypertensive effect.  To address this, we have used highly selective P2X3 receptor 94 
antagonists. Herein, we demonstrate the translatability of our pre-clinical findings to 95 
hypertensive humans.   96 
97 
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Results 98 
Hyperactivity of carotid bodies in hypertensive rats  99 
Carotid body afferent discharge was recorded from the carotid sinus nerve of the in situ 100 
preparation. Both basal discharge and chemoreflex evoked volleys (NaCN used to 101 
simulate hypoxia, 15─30 μg i.a.) were elevated in hypertensive versus normotensive 102 
rats (SH vs. Wistar: basal, 24.9 ± 2 vs 1.4 ± 0.3 spikes/s, respectively, P < 0.001; 103 
chemoreflex, 62.3 ± 3 vs 28.3 ± 2 spikes/s, respectively; P < 0.001, Fig. 1a─c). Next, low 104 
dose dopamine was used to inhibit carotid body discharge39. In SH rats in vivo, 105 
dopamine infusion (10 μg/kg/min i.v. as per39) depressed respiration, an effect not 106 
observed in Wistar rats (Fig. 1d), indicating the presence of carotid body tonicity in the 107 
hypertensive animals. Intracellular recordings revealed that physiologically 108 
characterised chemoreceptive primary afferent petrosal ganglion neurones from 109 
hypertensive rats in situ were more depolarised (-51.5 ± 0.9 vs -55.7 ± 1 mV; P < 0.001, 110 
Fig. 2a,c and Supplementary Fig. 1a), exhibited tonic firing (1.5 ± 0.8 vs 0 Hz; Fig. 2a) 111 
and displayed an enhanced chemoreflex evoked firing response to an equivalent dose of 112 
sodium cyanide (22.5 μg) compared to normotensive rats (123 ± 5 vs. 52 ± 3 spikes; P < 113 
0.001, Fig. 2a,d). In sum, compared to the normotensive rat, the carotid body of SH rats 114 
is hyperactive generating both aberrant tone and hyperreflexia.   115 
 116 
Chemoreceptive petrosal neurone excitability in SH rats 117 
We next compared the electrical excitability of chemoreceptive petrosal neurones and 118 
found that SH rats exhibited enhanced excitability to injected current pulses; for 119 
example, a 1nA current pulse evoked 25 ± 1.1 spikes vs 15 ± 1.7 spikes in Wistar rats 120 
(Supplementary Fig. 2a,b, n = 6; P < 0.05). Neither the membrane input resistance of 121 
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these cells (119 ± 3 vs 117 ± 9 MΩ; Supplementary Fig. 1c) nor whole cell capacitance 122 
was different between rat strains (Supplementary Fig. 1d). 123 
 124 
Normalizing petrosal neurone excitability in SH rats  125 
As P2X3 receptors are found in the carotid body of normotensive rats36 and associated 126 
with pathological afferent sensitisation in numerous other organs28,29,33 we assessed 127 
whether they were involved in carotid body dysfunction in SH rats in situ. In SH rats, 128 
focal delivery via a glass micropipette inserted into the ipsilateral carotid body of a 129 
highly selective non-competitive P2X3 receptor antagonist (AF-353; 15 nl, 20 μM40) 130 
caused hyperpolarisation (-9.9 ± 2.1 mV; n = 12, P < 0.001, Fig. 2b,c), total abolition of 131 
ongoing activity (Fig. 2b) and reduced chemoreflex sensitivity of petrosal 132 
chemoreceptive neurones (from 123 ± 5 to 34 ± 2 spikes; n = 12, P < 0.001, Fig. 2b,d). In 133 
normotensive animals in situ, AF-353 also caused hyperpolarisation (-4.4 ± 1.8 mV; n = 134 
10, P < 0.001, Fig. 2c) and reduced the chemoreflex evoked volley from 52 ± 3 to 32 ± 2 135 
spikes; n = 10, P < 0.001, Fig. 2b,d).  Both the magnitude of the hyperpolarisation and 136 
reduction in chemoreflex evoked spiking were greater in SH versus Wistar rats (P < 137 
0.001, Fig. 2c,d).  Notably, after P2X3 receptor antagonism, carotid body activation 138 
yielded comparable firing responses in petrosal neurones between rat strains (SH: 34 139 
vs. Wistar 32 spikes; NS), which was reversible in SH rats (Fig. 2b). After AF-353 140 
treatment the intrinsic firing response to injected depolarising current pulses was 141 
reduced in SH (e.g. at 1 nA: 25 ± 1 to 19 ± 1 spikes; P < 0.05, Supplementary Fig. 2a,b) 142 
but not Wistar rat neurones (15 ± 2 to 12 ± 2, NS). We next tested whether P2X3 143 
receptors were upregulated in SH rat petrosal neurones. 144 
 145 
Upregulated P2X3 receptors in petrosal neurones of SH rats 146 
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Single cell PCR analysis of characterised chemoreceptive petrosal ganglion neurones 147 
recorded from SH rats in situ revealed a >4 fold up regulation of P2x3 receptor mRNA 148 
relative to Wistar rats (Fig. 2e,f; n = 6, P < 0.001); this was confirmed at the protein 149 
level using western blot performed on carotid bodies (Fig. 3a). Interestingly, no change 150 
was found in P2x3 (or P2x2) receptor mRNA expression in non-chemoreceptive petrosal 151 
neurones (Supplementary Fig. 2e) indicative of specificity to chemoreflex neurones.  152 
There was no rat strain related change in: P2x2 receptor (Fig. 2f) and tyrosine 153 
hydroxylase (a known marker of glomus cells) mRNA expression in petrosal 154 
chemoreceptive neurones of SH rats (Supplementary Fig. 2c) or in chemoreceptive 155 
neurones located in the nucleus tractus solitarii (Supplementary Fig .2f). Fig. 3b 156 
shows co-localisation of P2X3 receptors with tyrosine hydroxylase immunopositive 157 
glomus cells (and axons, Supplementary Fig. 3a,b). Based on the up regulation of P2x3 158 
receptors in the petrosal neurones of SH rats, we tested whether there was a difference 159 
in sensitivity of these neurones to ATP between the rat strains.  160 
 161 
Sensitisation of SH rat chemoreceptive petrosal cells to ATP 162 
Application (15 nl) of ATP or α−β−methylene-ATP focally to the carotid body produced 163 
dose-dependent increases in the firing and membrane depolarisation of petrosal 164 
neurones. Notably, the petrosal neurones in the SH rat were more sensitive than those 165 
from Wistar rats:  for ATP the EC50% SH vs Wistar rat was 8.8 ± 2.2 vs 17.2 ± 1.3 (P < 166 
0.001; Fig. 3c,d) and for α−β−methylene-ATP the EC50% SH vs Wistar rat was 9.4 ± 2.1 167 
vs 16.2 ± 2.4 (P < 0.05; Supplementary Fig. 4a,b). These findings were consistent with 168 
greater P2X3 receptor-sensitive inward current evoked by ATP in chemoreceptive 169 
petrosal neurones (Fig. 3e,f). Next, we tested if antagonism of carotid body P2X3 170 
receptors lowered arterial blood pressure in SH rats. 171 
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 172 
Blocking P2X3 receptors systemically is anti-hypertensive 173 
One hour infusions of a highly selective non-competitive P2X3 receptor antagonist,AF-174 
219, were made at 1, 4 and 8 mg/kg/h, i.v.. This compound was preferred to the 175 
structurally related, more lipophilic antagonist AF-353, as AF-219 has been used 176 
clinically for other indications in humans29, and since it does not cross the blood brain 177 
barrier significantly its use in vivo was preferable. We performed a PK analysis to assess 178 
plasma concentrations in SH rats (Fig. 4a and Supplementary Fig. 5) and subsequently 179 
correlated these with the falls in systolic blood pressure (Fig. 4a). In SH rats, basal 180 
arterial pressure was 151±3/109±3 (SBP/DBP) mmHg. AF-219 produced dose-181 
dependent falls in arterial pressure (Fig. 4a); no response was observed in Wistar rats 182 
(Fig. 4b; Supplementary Fig. 6). At a dose of 8mg/kg/h SBP/DBP in SH rats fell by -183 
28±3/-26±4 mmHg (Fig. 4a; n = 7, P < 0.001). Heart rate and respiratory frequency also 184 
decreased (by -38±8 and -12±3 /min, respectively; Supplementary Fig. 6, n = 7, P < 185 
0.01). Interestingly, after carotid body resection a residual fall of -17±3 mmHg in SBP 186 
persisted with AF-219 infusion in SH rats (30 min, 8mg/kg/h; Fig. 4b, n = 7, P < 0.05; 187 
Supplementary Fig. 7). The chemoreflex evoked increase in arterial pressure in 188 
conscious SH rats was also reduced after systemic blockade of P2X3 receptors by AF-189 
219 (bolus doses given i.v. >1 mg/kg; n = 4, P < 0.05; Fig. 4c). We next determined the 190 
mechanisms by which arterial pressure was lowered in SH rats by P2X3 receptor 191 
blockade.  192 
 193 
P2X3 receptor blocker reduces sympathetic tone in SH rats 194 
We evaluated the effect of P2X3 receptor antagonism on cardiovascular autonomic 195 
activity. Ongoing basal levels of thoracic SNA recorded in situ were reduced from 196 
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20.8±2.2 to 13.7±2.5 μV (Fig. 5a─c; n = 12, P < 0.001) following focal delivery of AF-353 197 
(15 nl, 20 μM) to carotid bodies bilaterally in SH rats. This reduced value was similar to 198 
levels in normotensive rats either before (12.3±2.6 μV) or after AF-353 application 199 
(11.7±2.3 μV, Fig. 5c; n = 12, NS). Chemoreflex evoked increases in expiratory 200 
modulated SNA were 209±12% and 131±11% for SH and Wistar rats respectively, and 201 
after AF-353 were reduced significantly to 76±11% and 69±7.8% in SH and Wistar rats, 202 
respectively (Fig. 5a─e, n = 12, P < 0.001); these new basal values were not different to 203 
one another. Following drug washout, the depressant effects on SNA was reversed 204 
(basal and reflex evoked; Fig. 5b).   205 
 206 
We replicated these data using TNP-ATP (Supplementary Fig. 8). a high affinity, non-207 
selective P2X receptor antagonist that inhibits P2X1, P2X3 and heteromeric 208 
P2X2/3 with a 1000-fold selectivity over P2X2, P2X4 and P2X7 receptors that is 209 
structurally distinct to AF-353. This evidence supports AF-353 blocking P2X3 210 
homomeric and P2X2/3 heterotrimeric receptors rather than non-selective actions on 211 
ionic conductances and/or other receptors.  212 
 213 
Recordings were made from renal sympathetic nerves using radio-telemetry in 214 
conscious SH rats in vivo during chronic systemic P2X3 receptor antagonism using AF-215 
219. This reduced both the basal renal sympathetic activity (-37±13 normalised units 216 
relative to baseline, Fig. 5f; P < 0.05) and the chemoreflex evoked increase in renal 217 
sympathetic activity (Fig .5g,h; P < 0.05). Spontaneous renal sympathetic baroreflex 218 
gain was enhanced after AF-219 (0.14±0.07 vs 0.01±0.02 %.mmHg-1; P < 0.05) but not 219 
vehicle infusion. Although no changes in autonomic activity to the heart were detected 220 
in conscious SH rats after AF-219 infusion (Supplementary Fig. 9a,b), spontaneous 221 
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cardiac baroreflex was increased (0.13±0.04 to 0.27±0.05 ms/mmHg, Supplementary 222 
Fig. 9c; P < 0.001).  We next tested the translatability of the SH rat data and potential 223 
use of P2X3 receptor antagonist in human hypertension.  224 
 225 
Translating carotid body P2X3 receptors to human hypertension 226 
If P2X3 receptors within the carotid body are to be considered a novel anti-227 
hypertensive target in humans, then evidence for their presence and pharmacokinetics 228 
of suitable antagonist are essential first steps. Carotid bodies were obtained from 229 
cadavers and processed for P2X3 receptors immunocytochemistry (n = 5) and western 230 
blot (n = 4). P2X3 receptor antibody specificity was determined (Supplementary Fig. 231 
10). P2X3 receptor expression was prevalent in human carotid body (Fig. 6a and 232 
Supplementary Fig. 11a) showing co-expression with tyrosine hydroxylase, a marker 233 
for glomus cells. Axons within the carotid body also expressed P2X3 receptors 234 
(Supplementary Fig. 11b).  This expression pattern was similar to that seen in the SH 235 
rat (Fig. 3b).  236 
 237 
With the presence of P2X3 receptors in hypertensive human carotid body, we next 238 
assessed whether there was tonicity in the carotid body of hypertensive humans by 239 
chemical and reversible inactivation of it. In six hypertensive humans, minute 240 
ventilation was measured during low dose dopamine infusion (5 min; 2 μg/kg/min i.v.) 241 
as described previously to inactivate the carotid body38. A bi-phasic response in minute 242 
ventilation to dopamine was observed (Fig. 6c) comprising a depression (-1.28± 0.52 243 
L/min; P < 0.05) and over shoot following dopamine (1.28± 0.41 L/min; P < 0.05) 244 
relative to vehicle infusion. These data indicate that the carotid body of hypertensive 245 
humans can generate tonic drive and that dopamine infusion allows identification of it. 246 
12 
 
247 
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Discussion  248 
Many transmitter mechanisms mediating reflex responses to hypoxia have been 249 
described within the carotid body and may contribute to its sensitisation in disease 250 
states; these include: TASK and ASIC channels14,25, hydrogen sulphide23,24, carbon 251 
monoxide24, nitric oxide24 and carotid body blood flow27. However, in vitro studies have 252 
also shown a major role for ATP release from glomus cells in response to hypoxia in 253 
both rat30, cat31 and human35. Whether there is a link between ATP release and any of 254 
the aforementioned mechanisms remains an open question. Moreover, P2X2 and P2X3 255 
receptor subunits were both found to be present in the rat carotid body36 and using co-256 
cultures of glomus and petrosal cells in vitro Nurse and colleagues demonstrated that 257 
ATP acted via P2X receptors to excite petrosal neurones36. This evidence was based on 258 
using suramin, a weak and non-selective P2X antagonist. P2X2-containing channels 259 
(P2X2 homotrimers and/or P2X2/3 heterotrimers) likely dominate the normal 260 
physiological ventilatory response to hypoxaemia as the P2X2 single and P2X2 + P2X3 261 
double KO mice, but not the P2X3 single KO, showed ventilatory hyporeflexia37.  Thus, 262 
P2X3 subunit expression changes seem associated with pathological sensitisation of 263 
carotid body reflexes.  264 
 265 
In the present study, using selective antagonists, we found that both exogenous and 266 
endogenous ATP released from the carotid body can act on P2X3 subunit containing 267 
receptors on petrosal neurons. A caveat is that we cannot fully establish the relative 268 
contribution of homotrimeric P2X3 versus heterotrimeric P2X2/3 receptors in such 269 
responses, although the antagonists we used have higher affinity for P2X3 homotrimeric 270 
receptors28, and a P2X3 heterotrimeric upregulation in carotid body could account for 271 
increased ATP sensitivity per se, as this channel form in recombinant studies displays 272 
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significantly lower EC50 values to the nucleotide40. Our voltage clamp data indicate a 273 
non-desensitising current to α-β-methyl ATP and probable involvement of P2X3 274 
homomeric and P2X2/3 heteromeric receptors. Our data provide the first evidence that 275 
P2X3 receptors in the carotid body play a vital role in controlling its reflex sensitivity in 276 
SH but not normotensive rats.   277 
 278 
Up-regulation of P2X3 receptors in the carotid body appears, in part, causal for the 279 
aetiology of the tonicity, hyperreflexia of chemoreceptive petrosal neurones and 280 
downstream hyperactivity of the sympathetic nervous system in SH rats. We 281 
acknowledge that chemoreceptive petrosal neurones may have a larger receptive field 282 
in the carotid body of SH vs Wistar rats contributing to their hyperactive state. Notably, 283 
upregulated P2x3 receptor mRNA was exclusive to chemoreceptive petrosal neurones 284 
(i.e. not upregulated on non-chemoreceptive petrosal cells). The carotid body tonicity 285 
we report from in situ preparations (1.5 Hz per petrosal neuron) most likely 286 
underestimates that in conscious SH rats as recordings were made in hyperoxia, a 287 
condition known to temper carotid body discharge14,20; this may also explain the dearth 288 
of activity in neurones recorded from Wistar rats.  Whether P2X3 receptor up-289 
regulation alone is sufficient for the pathological carotid body signalling in the SH rat 290 
(without the need for increased ATP release or reduced ATP clearance) is unclear. 291 
However, given that the microvasculature of the carotid body is hypertrophied in the SH 292 
rat41 and the possibility that arterioles feeding the carotid body receive high 293 
sympathetic drive41, the tissue is likely to be hypoxic/hypercapnic – a condition known 294 
to induce ATP release42. Additionally, inflammation, known to be present in the carotid 295 
body of SH rats41, will also drive ATP release43.  296 
 297 
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The association of P2X3 receptor up-regulation and aberrant afferent signalling is not 298 
new28 but consistent with sensitisation of visceral sensing mechanisms from, for 299 
example, the bladder44,45, urinary tract46, larynx 29, lungs47, gastro-intestinal-tract48,49 300 
and skeletal muscle50 in numerous diseased states including chronic pain51.  Elucidation 301 
of the mechanisms controlling P2x3 receptor expression at both transcriptional and 302 
cytosolic trafficking levels within the carotid body and other organs now becomes an 303 
important issue to allow translation into the clinical arena.  304 
 305 
The finding that P2X3 receptor activation evoked a rapidly inactivating current in vitro52 306 
seems inconsistent with an ability of P2X3 receptors to maintain tonic drive from the 307 
carotid body (or any organ). Notably, low pH, a postulated condition in the carotid body 308 
of SH rats (see above;41), can potentiate P2X3 receptor inward currents and reduce de-309 
sensitisation53. Furthermore, the concept has been developed that P2X3 receptor 310 
activation may lead to local generator potentials and calcium transients in afferent 311 
terminals that lowers the threshold for activation by any other excitatory agent, as 312 
described in somatosensory nociceptor C-fibres as leading to a condition of hyperalgesic 313 
priming54,55.  Such threshold attenuation and chemoceptive priming may be under the 314 
control of P2X3 receptor in the carotid body, although we do not rule out possible 315 
emergence of P2X2/3 heteromeric receptors, as these channels show less rapid de-316 
sensitisation52, which is consistent with our voltage clamp data (Fig. 3e,f).   317 
 318 
We found a robust dose-dependent lowering of arterial pressure following systemic 319 
administration of AF-219 in SH rats. That a fall in blood pressure was seen in rats with 320 
Goldblatt hypertension (W. Pijacka, F.M. McBryde & J.F.R. Paton – unpublished) suggests 321 
this is not restricted to the SH rat. We propose that the effect of P2X3 receptor 322 
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antagonism is, in most part, acting within the carotid body but not exclusively as the 323 
antagonist induced fall in arterial pressure was substantially reduced but not abolished 324 
after carotid body ablation (Fig. 4b and Supplementary Fig. 7). Further support for a 325 
direct action of the antagonist at the carotid body is that the fall in arterial pressure was 326 
accompanied with a reduction in sympathetic activity in vivo, a mechanism for the 327 
arterial pressure reduction, which was also found following direct injection of AF-353 328 
into the carotid body in situ. The remaining residual depressor response seen with AF-329 
219 after carotid body ablation suggests a contribution from other sensory afferents in 330 
which P2X3 receptors have become active. We propose this includes glomus tissue in 331 
the thorax and abdomen but this remains to be confirmed. Mechanistically, the decrease 332 
in sympathetic activity included a reduction in its respiratory modulation, particularly 333 
its expiratory component. It is this component that is upregulated in numerous models 334 
of hypertension56,57 supporting the importance of the central respiratory generator as a 335 
major driver of autonomic imbalance in hypertension57. We also found an improvement 336 
in the spontaneous cardiac baroreceptor reflex, possibly reflecting the removal of the 337 
inhibitory influence of the carotid body on the carotid sinus baroreceptor reflex as 338 
reported previously in both SH rats20 and human hypertensives58; this may contribute 339 
to the sympatho-inhibition and anti-hypertensive response of P2X3 receptor 340 
antagonism in the SH rat. 341 
 342 
The clinical significance of the synergy of up-regulated P2X3 receptor expression in the 343 
carotid body and petrosal neurones with emerging pathology should not be 344 
underestimated. It follows that administration of a P2X3 receptor antagonist should 345 
attenuate aberrant signalling without affecting physiological function. Data herein 346 
supports this logic, as carotid body tonic drive and hyperreflexia were abated yet the 347 
17 
 
system remained physiologically responsive to stimulation akin to control animals (Fig. 348 
2b). This is entirely consistent with a recent human trial to treat chronic pathological 349 
cough where the latter was abated but physiological/protective cough reflexes did not 350 
appear to be altered29. Peripheral chemoreception also has both regulatory and 351 
protective reflex functions59. Simultaneously abolishing pathological signalling while 352 
preserving normal carotid body function with a P2X3 antagonist such as AF-219 is an 353 
ideal outcome clinically that would be paramount in drug safety and target specificity. 354 
An issue may be the known adverse effect of P2X3 receptor antagonism affecting taste 355 
perception29 but appropriate dosing may negate this.  356 
 357 
Over the last 20 years there has been a dearth of novel anti-hypertensive therapeutics 358 
(e.g.7). We speculate that P2X3 receptor antagonism may be most efficacious in a sub-359 
population of uncontrolled hypertensive humans with demonstrable aberrant carotid 360 
body activity and an overactive sympathetic nervous system.  The existence of P2X3 361 
receptors in the carotid body of hypertensive human, the release of ATP from human 362 
glomus cells in response to hypoxia35 and the ability of dopamine to select those 363 
individuals with aberrant carotid body discharge (Fig. 6c) supports our contention of a 364 
translational trial to test the anti-hypertensive effect of P2X3 antagonism; this study 365 
now awaits commencement. 366 
 367 
 368 
Methods  369 
Methods and any associated references are available in the online version of the paper. 370 
 371 
 372 
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Figure legends 618 
 619 
Figure 1 620 
Overactive peripheral chemoreceptors in spontaneously hypertensive (SH) rats.  621 
Original recordings of carotid sinus nerve (CSN; (a)) activity showing both basal 622 
discharge (a,b) and that evoked reflexly by stimulating the carotid body with sodium 623 
cyanide (a,c; 22.5 μg NaCN i.a., arrowed in a) in SH and Wistar rats. CSN data from the in 624 
situ perfused preparation. (one-way ANOVA Bonferroni post-test; n = 10 or 11, ***P < 625 
0.001). (d), dopamine infusion (10 μg/kg/min i.v.) while recording ventilation 626 
frequency in conscious radio-telemetered Wistar and SH rats (n = 5 each) before and 627 
after selective carotid body resection (SHR CBR). One-way ANOVA Dunnett's post-test.  628 
* P < 0.05. ***P < 0.001. All data are mean ± s.e.m. 629 
 630 
Figure 2 631 
P2X3 receptor mediated hyperreflexia and tonicity of chemoreceptive petrosal 632 
neurones in spontaneously hypertensive (SH) rats are associated with upregulation of 633 
P2x3 receptor mRNA.  (a), two representative whole cell patch clamp recordings from 634 
chemoreceptive petrosal neurones from a Wistar (left) and SH rat (right) recorded in 635 
the in situ preparation. Ongoing discharge, membrane potential and reflex evoked 636 
responses to carotid body stimulation (NaCN, sodium cyanide, 22.5 μg i.a. arrowed) 637 
were compared between rat strains. (b), responses of neurones in (a) following P2X3 638 
receptor blockade with AF-353 (20 μM, 20 nl), which was delivered focally into the 639 
carotid body by picoinjection. Effects in SH rats were reversed upon washout. Grouped 640 
mean data summarising rat strain related differences and responses in membrane 641 
potential (c; see also Supplementary Fig. 1a,b) and chemoreflex evoked firing 642 
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responses (d) before and after P2X3 receptor antagonism. Data in (c) are mean ± s.d. 643 
and those in (d) are mean ± s.e.m. One-way ANOVA Bonferroni post-test (n = 12 SH, n = 644 
10 Wistar rats).  The difference in expression of P2x3 and P2x2 receptor mRNA from 645 
petrosal chemoreceptive neurones (identified using sodium cyanide, NaCN, 22.5 μg, i.a.) 646 
during whole cell patch (e) was revealed using single cell PCR ((f); n = 5 or 6). Two-way 647 
ANOVA Bonferroni post-test.  Data in (f ) are mean ± s.e.m and were generated from the 648 
in situ arterially perfused preparation.  *** P < 0.001. 649 
 650 
Figure 3 651 
In spontaneously hypertensive (SH) rats P2X3 receptor protein was upregulated in 652 
carotid body and chemoreceptive petrosal neurones were sensitised to ATP relative to 653 
Wistar rats.  (a), difference in P2X3 receptor protein in the carotid body of Wistar 654 
relative to SH rats (Mann–Whitney t-test; n = 4 or 5).  (b) P2X3 receptor 655 
immunofluorescence labelling on glomus cells identified by the presence of tyrosine 656 
hydroxylase (TH; n = 3 Wistar, n = 3 SH rats).  See, Supplementary Fig. 10 for control 657 
data on the specificity of the P2X3 receptor antibody. Scale bars 100 μm (top left) and 658 
25 μm all others. (c), ATP microinfused into the carotid body while whole cell recording 659 
(current clamp) from petrosal chemoreceptive neurones in Wistar (n = 10) and SH rats 660 
(n = 13). (d), rat strain comparison of the ATP (applied to the carotid body) evoked 661 
membrane depolarisations from petrosal chemoreceptive neurones in both rat strains. 662 
AUC, area under the curve.  (e), voltage clamp data indicating the ATP (applied to the 663 
carotid body) evoked inward current from identified petrosal chemoreceptive neurones 664 
before and after application to the carotid body of the P2X3 receptor antagonist (AF-665 
253, 20 μM) and the non-selective P2X receptor antagonist, suramin (100 μM) in Wistar 666 
(top traces; n = 12) and SH rats (bottom traces; n = 12). (f), rat strain differences in the 667 
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AF-353 sensitive ATP evoked inward current. Neurophysiological data were from the in 668 
situ arterially perfused preparation and comparisons made using an unpaired t-test. All 669 
data are mean ± s.e.m. * P < 0.05; *** P < 0.001. 670 
 671 
Figure 4 672 
P2X3 receptor antagonism lowers arterial pressure in conscious spontaneously 673 
hypertensive (SH) rats.  (a), Intra-venous infusions of a P2X3 receptor antagonist (AF-674 
219, 1─8 mg/kg/h) showing dose-dependent responses in systolic blood pressure 675 
(SBP). Solid lines indicate the blood pressure responses and dotted lines the predicted 676 
PK value based on plasma sampling (see also Supplementary Fig. 5). (b), Comparison 677 
of the SBP responses induced with 8 mg/kg/h AF-219 i.v. in SH (n = 7) and Wistar rats 678 
(n = 7), and in SH rats before and after carotid body resection (CBR; n = 7). (c), the 679 
peripheral chemoreflex evoked pressor responses in SBP during infusion of vehicle and 680 
0.5─8 mg/kg/h AF-219. Data from seven conscious radio-telemetered rats are mean ± 681 
s.e.m. One-way ANOVA Dunnett's post-test. * P < 0.05, ** P < 0.01, *** P < 0.001.  682 
 683 
Figure 5 684 
The anti-hypertensive action of P2X3 receptor antagonism is associated with a 685 
reduction in sympathetic activity in spontaneously hypertensive (SH) rats in situ and in 686 
vivo.  A comparison of the effect of a P2X3 receptor antagonist (AF-353; 20 μM, 15 nl) 687 
applied locally to both carotid bodies on the ongoing thoracic chain sympathetic activity 688 
(arrow, raw: tSN; integrated: ∫tSN) and the sympathetic nerve reϐlex response (arrow 689 
head) to peripheral chemoreceptor stimulation (evoked by NaCN, 22.5 μg i.a.) in 12 690 
Wistar (a) and 12 SH rats (b). The effect of P2X3 receptor antagonism within both 691 
carotid bodies on the basal (c), inspiratory- (d) and expiratory (e) modulated tSN for 692 
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both rat strains is shown (n = 12 each). Inspiratory and expiratory modulation of tSN 693 
was determined using averaged triggering from the phrenic nerve (PN). One-way 694 
ANOVA Bonferroni post-test; data are mean ± s.e.m. from in situ rat preparations (n = 12 695 
each strain).  (f), renal sympathetic nerve activity (RNA) recorded from conscious radio-696 
telemetered in vivo SH rats (n = 5) during infusions of AF-219 (8 mg/kg/h i.v.). Note the 697 
similar time course of the response in RNA to the fall in systolic blood pressure depicted 698 
in Fig. 4(a).  A representative example of the peripheral chemoreflex evoked 699 
sympathoexcitatory response (NaCN 22.5 μg i.a.) in a conscious radio-telemetered SH 700 
rat before and after AF-219 (g) with mean data shown in (h), which includes drug 701 
washout data.  Repeated measures one-way ANOVA, with Holm-Sidek post-hoc 702 
comparison.  n = 5, * P < 0.05, *** P < 0.001.  703 
 704 
 705 
Figure 6 706 
P2X3 receptor expression and aberrant tone generation in hypertensive human carotid 707 
bodies.  (a), on the left is a section of a carotid body from a human cadaver showing 708 
P2X3 receptor immunofluorescence (green) with the nuclear stain - DAPI (blue; scale 709 
bar 100 μm).  On the right, high power confocal images showing co-localisation of P2X3 710 
receptors, tyrosine hydroxylase (TH) and DAPI (scale bar 25 μm).  Data repeated in five 711 
human carotid bodies.  See Supplementary Fig. 10 for P2X3 receptor antibody control 712 
and Supplementary Fig. 11 for axonal labelling. (b), western blot of the P2X3 receptor 713 
protein in human carotid body (n = 4). (c), low dose dopamine infusion (2 μg/kg/h i.v.) 714 
was used to inactivate the carotid bodies in six awake hypertensive humans (each 715 
colour coded) while recording minute ventilation in the supine position. A dextrose 716 
vehicle infusion was used as control and reference at time zero.  The mean (± s.e.m.) 717 
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response is indicated by the black dotted line. Note appearance of a rebound 718 
hyperventilatory response post-dopamine infusion.  One-way ANOVA Bonferroni post-719 
test. * P < 0.05 vehicle versus peak depression; ** P < 0.01, depression versus rebound 720 
(mean of 5 min); † P < 0.05, vehicle versus rebound.  721 
 722 
 723 
724 
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Online Methods 725 
 726 
A. Animal studies 727 
All procedures conformed to the UK Animals (Scientific Procedures) Act 1986, and were 728 
approved by the University of Bristol ethical review committee. We used male 729 
spontaneously hypertensive (SH) or Wistar rats, which were bred within the animal 730 
facility of the University of Bristol. Animals were selected from different litters and 731 
housed with controlled temperature (21 ± 2 ºC) and humidity (55 ± 10%). Wistar and 732 
SH rats were exposed to 12 hour day-night shift with unlimited access to food and 733 
water. We used rats either 4-5 weeks old (70-100 g) for in situ preparations or 14-16 734 
weeks for in vivo radio-telemetry. Power calculations were based on: determining 735 
response magnitude (arbitrarily or based on previous reports or pilot experiments), 736 
data variance (our previous experience, published papers, pilot experiments), taking 737 
into consideration number of drugs to be tested and drug doses, and expected technical 738 
success rate of each type of experiment.  Given the highly technical nature and longevity 739 
of the studies it was not possible to blind them.   740 
 741 
Arterially perfused in situ juvenile rat preparation  742 
Male Wistar or SH rats, 4-5 weeks, weighing 70–100 g were prepared as originally 743 
described60. In brief, rats were anesthetized deeply using isoflurane (5%). Anesthetic 744 
depth was assessed by a failure to respond to a noxious pinch of either a paw or the tail. 745 
Anesthetized rats were transected below the diaphragm, their upper body submerged 746 
in ice-cooled Ringer solution and decerebrated pre-collicularly by gentle aspiration. The 747 
preparation was skinned, transferred to a recording chamber and a double-lumen 748 
catheter was inserted into the descending aorta. One lumen was used to deliver 749 
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perfusate pumped using a roller pump (Watson Marlow 505S). The perfusate was an 750 
isosmotic Ringer solution (containing in mM: NaCl 120, NaHCO3 24, KCl 5, CaCl2 2.5, 751 
MgSO4 1.25, KH2PO4 1.25, glucose 10) containing an oncotic agent (polyethylene glycol, 752 
1.5%; Sigma-UK), gassed with carbogen (95% O2 and 5% CO2), warmed to 32 °C, pH 7.3 753 
after carbogenation, and filtered using a nylon screen (pore size: 25 μm diameter). A 754 
side connector to this catheter allowed administration of drugs directly into the arterial 755 
circulation. The second lumen of the catheter was used to monitor aortic perfusion 756 
pressure. The left phrenic nerve was isolated and its activity (PNA) recorded from the 757 
cut central end using a glass suction bipolar electrode held in a 3-D micromanipulator. 758 
Rhythmic ramping PNA gave a continuous physiological index of preparation viability. 759 
After respiratory-related movements commenced, a neuromuscular blocker 760 
(vecuronium bromide, 40 μg.ml−1, Norcuron Organon Teknika) was added to the 761 
perfusate to stabilize mechanically the preparation. Sympathetic nerve activity (SNA) 762 
was also recorded from the thoracic or lumbar sympathetic chain using a bipolar glass 763 
suction electrode. All nerve signals were AC-amplified, band-pass filtered (0.5 Hz−5 764 
kHz), rectified and integrated and sampled at 2-5 kHz. At the end of each experiment the 765 
noise level was measured after application of lidocaine (2%) to the sympathetic chain; 766 
this level was subtracted from the integrated signal. The head of the preparation was 767 
fixed by ear bars. 768 
 769 
Whole cell recordings from chemoreceptive neurones 770 
The carotid body/carotid sinus nerve/petrosal ganglion complex was isolated on the 771 
animal’s right side. Using recently described techniques57,61 whole cell patch clamp 772 
recordings of chemoreceptive petrosal ganglionic or NTS neurones was performed with 773 
electrodes filled with a solution containing the following (in mM): 130 K-gluconate, 4.5 774 
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MgCl2; 14 trisphosphocreatine, 10 HEPES; 5 EGTA; 4 Na-ATP; 0.3 Na-GTP; pH 7.3, and 775 
∼300 mOsmol and had resistances of 3–8 MΩ when tested in bath solution. Current- 776 
and voltage- clamp experiments were performed using an Axopatch-200B integrating 777 
amplifier (Molecular Devices) and pClamp acquisition software (version 10.0, Molecular 778 
Devices). Gigaseals (>1 GΩ) were formed, and whole-cell configuration was obtained by 779 
suction. To allow stable whole cell recordings, the petrosal ganglion was opened along 780 
its lateral aspect. A mesh grid was lowered onto the ganglion for stabilization, while 781 
permitting visualisation of the petrosal ganglia. We used electrical stimulation of the 782 
carotid sinus nerve (the axons of petrosal neurones) to find the chemosensitive petrosal 783 
and NTS neurones as characterised by their excitatory response to sodium cyanide 784 
injected into the aorta (0.03%, 50 μl). ATP (15 nl of 0.5, 2, 10, 20, 40, 100 mM) or α-785 
β−methylene ATP (15 nl of 0.5, 2, 10, 20, 40, 100 mM) or AF-353 (15 nl of 20 μM; a P2X3 786 
receptor antagonist)40 were injected into the carotid body using a 2 μm tip diameter 787 
glass microelectrode attached to a picopump (Picospritzer II, Parker Instrumentation).  788 
 789 
Single petrosal neurone PCR 790 
The cytoplasm of the chemosensitive petrosal and NTS neurones were pulled into a 791 
patch pipette with a slight negative pressure as described recently61. The cytoplasm was 792 
then placed into a microtube containing High Capacity cDNA Reverse Transcription Kit 793 
reagents (Life Technologies) and nuclease-free water for subsequent transcription in a 794 
thermocycler (Mastercycler Gradient, Eppendorf). A pre-amplification of the cDNA was 795 
performed using the TaqMan PreAmp Master Mix Kit (Life Technologies) with the 796 
following probes: Rn04219592_g1 (P2x2), Rn00579301_m1 (P2x3), 797 
TH: Rn00562500_m1, Post-synaptic density-95: Rn00571479_m1 and β-Actin: 798 
NM_031144.2 (reference gene). The pre-amplification protocol consisted of a hold 799 
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temperature at 95°C during 10 minutes and 14 cycles of 95°C and 60°C during 15 s and 800 
14 minutes, respectively. The reactions for the single-cell qRT-PCR were performed in 801 
singleplex and triplicate (StepOnePlus System, Applied Biosystems) using the same 802 
probes described above and the TaqMan Universal PCR Master Mix kit (Life 803 
Technologies) according to the manufacture's recommendations. Water was used 804 
instead of cDNA as a negative control. β-actin was used as a control gene to normalise 805 
the reactions. The relative quantitation was determined by the ΔΔCt method. For each 806 
sample, the threshold cycle (Ct) was determined and normalised to the average of the 807 
housekeeping genes ( ). The fold change of mRNA content in 808 
the sample of petrosal neurones from SHR relative to the Wistar group was determined 809 
by , where . Data are presented as mRNA expression 810 
relative to the Wistar group. Dual probing of mRNA included: TH and PSD-95 in 11 811 
petrosal chemoreceptive cells from Wistar rats; TH and PSD-95 in 9 petrosal 812 
chemoreceptive cells from SHR; P2x2 and P2x3 receptor expression in 6 petrosal 813 
chemoreceptive cells from Wistar and 5 petrosal chemoreceptive cells from SHR. 814 
 815 
In vivo blood pressure and renal nerve monitoring 816 
Most surgical techniques were described previously20. Rats were anaesthetised with 817 
ketamine (100mg/ml; Vetalar, Zoetis, London, UK)/medetomidine hydrochloride (1 818 
mg/ml Domitor, Elanco Animal Health, Hampshire, UK) injected intra muscularly.  819 
For blood pressure recording only, an incision was made in the midline of the abdomen 820 
and the abdominal aorta was exposed and cannulated just above the iliac bifurcation. 821 
The cannula of the transmitter (PA-C40; DSI, USA) was inserted until the tip rested just 822 
below the left renal artery branch point, and held in place using a tissue adhesive 823 
(VetBond, 3M, USA) and cellulose matrix. The transmitter body was placed in the 824 
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abdominal cavity. Animals were allowed a seven days recovery period. A non-steroidal 825 
anti-inflammatory analgesic, was administered for 3 to 5 days postoperatively (0.006 826 
mg/100g of Metacam, Boehringer Ingelheim, Germany). Some rats were fitted with 827 
heparinised (TDMAC, Plolysciences Inc., Eppelheim, Germany) catheters placed into 828 
right jugular and left femoral vein for blood sampling and drug infusions, respectively. 829 
The catheter placed in the right jugular vein was perforated according to the protocol62. 830 
Animals were allowed five days recovery post vein catheterisation. Catheters were 831 
flushed with heparinised saline solution (0.9 % Saline/ 100U Heparin) every other day 832 
in order to maintain their patency.  833 
 834 
For renal nerve recording, rats were implanted with telemetric devices (TRM56SP; 835 
Millar Inc, Houston, Texas, USA). Details for blood pressure procedures are given above. 836 
For renal nerve recording, the right renal artery was exposed via a retroperitoneal 837 
approach, the renal nerves gently freed from surrounding connective tissue and a small 838 
piece of parafilm placed underneath. The renal nerve(s) were then lifted over bipolar 839 
silver wire recording electrodes, isolated with a biocompatible silicone elastomer 840 
(Kiwk-Sil, WPI, Eu), and the nerve/electrode complex secured in place using tissue 841 
adhesive and cellulose mesh. The incision was closed, and rats recovered for at least 842 
seven days post-operatively, with analgesic treatment for 3 days (buprenorphine, 0.01 843 
mg/kg per dose). 844 
 845 
Experimental protocols for in vivo rat studies 846 
These studies were repeated by two researchers working independently. Drug infusions 847 
(i.v.) were carried out in rats housed singularly. Animals were acclimatised to 848 
experimental environment for at least 2 hours. At this time blood pressure remained 849 
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stable. AF-219 was dissolved in 0.9% saline containing 10 mM HCl (vehicle).  In some 850 
animals in which arterial blood pressure was measured, a PK analysis of AF-219 was 851 
performed by withdrawing blood from the jugular catheter at two time points: one hour 852 
from the start of infusion and one hour post infusion.  Rats received an infusion of 853 
vehicle and 1, 4 and 8 mg/kg/h AF-219 for 60 minutes at 5 ml/kg/h into their femoral 854 
vein followed by a 60 minute washout period. Administration order of the drug doses 855 
and vehicle was randomized. These doses were selected by modelling pharmacokinetic 856 
data to obtain a pharmacokinetic profile in rats similar to that achievable in humans.  857 
The modelling was validated by quantifying AF-219 plasma concentrations after the 60 858 
minute infusion period by using an HPLC-MS/MS assay and stable-labelled AF-219 as 859 
internal standard. The peripheral chemoreflex was tested with sodium cyanide (0.1 ml 860 
bolus i.v. 0.04% NaCN; BDH, Poole, UK, flushed with 0.9% saline (0.1 ml)). A bolus 861 
injection of sodium cyanide (0.04% in 0.1 ml) was given 45 minutes before, and 60 and 862 
90 minutes after the beginning of the infusion to check for chemoreflex sensitivity. Rats 863 
were allowed 24 hour recovery between vehicle/drug and each drug dose. Infusions 864 
were carried using a standard syringe pump (Harvard apparatus, MA, USA). Dopamine 865 
hydrochloride was infused (10 μg/kg/min; Sigma-Aldrich Company Ltd., Dorset, UK) to 866 
reversibly inactivate carotid bodies and assess their tonicity by measuring arterial 867 
pressure, heart rate and respiratory frequency.  868 
 869 
Rats tested with NaCN and dopamine hydrochloride underwent selective bilateral 870 
carotid body resection. Via a midline incision through the skin on the ventral surface of 871 
the neck, and using a binocular dissecting microscope the carotid bifurcation was 872 
identified. From a medial perspective the carotid body was visualised and ablated using 873 
fine watchmakers forceps. Effective carotid body ablation was confirmed by an absence 874 
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of a cardiovascular and respiratory response to NaCN (i.v.). Animals were allowed six 875 
days for recovery. Once confirmation of selective carotid body ablation rats were 876 
infused with vehicle, AF-219 (8 mg/kg/h i.v.) and dopamine hydrochloride (10 877 
μg/kg/min i.v.) on separate days. 878 
 879 
Western blotting and immunocytochemical studies 880 
Rat left and right carotid bifurcations were surgically removed from deeply 881 
anaesthetised rats and immediately transferred into ice cold saline. Carotid bodies were 882 
dissected under a Motic K Series Stereo Microscope (Ted Pella, Inc.). Five SH and four 883 
Wistar rats were used for western blotting and six SH and six Wistar rats were used for 884 
immunohistochemistry. Specificity of the P2X3 receptor antibody was validated 885 
(Supplementary Fig. 10).  Carotid artery bifurcations were removed and carotid 886 
bodies dissected from these and snap frozen in liquid nitrogen (left and right together) 887 
for western blotting or they were fixed in ice cold methanol/DMSO (4:1) for 888 
immunohistochemistry. The relative expression of protein corresponds to one pair of 889 
carotid bodies (left and right). Immunohistochemistry was carried out on the whole 890 
mount rat carotid body and anti-P2X3 receptor antibody (APR026AN0202, Alomone, 891 
Israel). Incubation with anti-P2X3 and TH antibody was carried out in 2% goat serum 892 
over night at 4°C, gently mixed. All other details are given below (Human Studies) and 893 
similar to those used in the human studies.  894 
 895 
Statistical analysis 896 
Digitally transmitted arterial pressure and renal SNA signals were collected 897 
continuously during the drug or vehicle infusion period. Arterial pressure was 898 
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measured during resting conditions. The renal SNA signal was amplified, filtered (50-899 
5000 Hz), full-wave rectified and integrated using a low pass filter with a 20 ms time 900 
constant. Arterial pressure and renal SNA were sampled at 1k Hz using a 1401 901 
acquisition system and purpose-written scripts in Spike2 software (Cambridge 902 
Electronic Designs, Cambridge, UK). From the arterial pressure we derived pulse 903 
pressure, heart rate and respiratory frequency. Power spectral analysis was performed 904 
on heart rate using Spike 2 software (CED instruments, Cambridge, UK). The inter-burst 905 
interval in renal SNA was taken as the baseline noise level, and removed from the signal. 906 
The renal SNA signal was then scaled, with the 30 minutes immediately prior to infusion 907 
taken as the 100% normalised level. We report the change in renal SNA with AF-219 908 
relative to vehicle. The mean differences between baseline and treatment were analysed 909 
by the GraphPad Prism 6 (GraphPad Software, Inc., USA). We analysed the spontaneous 910 
cardiac and renal sympathetic baroreflex gain (sBRG). The sBRG for the arterial 911 
pressure–renal SNA relationship was calculated for 10 minutes immediately before, and 912 
the final 10 minutes of the 60 minute infusion period of AF-219 or vehicle. Diastolic 913 
pressure was smoothed over 5 beats, and positive or negative pressure ramps of at least 914 
5 consecutive beats were automatically identified using Spike2 scripts (CED 915 
instruments, Cambridge, UK). All ramps where both heart rate and renal SNA opposed 916 
the change in the corresponding DBP ramp were included for analysis. As described 917 
earlier, renal SNA was normalised with the baseline (pre-infusion) level set at 100%. A 918 
paired student t-test was used to compare the renal SNA sBRG between vehicle and AF-919 
219 infusions. 920 
 921 
The type of statistical test performed is indicated in the figure legends.  Data were 922 
normally distributed and variance was comparable between groups statistically 923 
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compared. Unless stated in the figure legends, data were expressed as mean ± SEM are 924 
presented and data were assumed significant when P < 0.05.  925 
 926 
Drugs 927 
Two highly potent and selective non-competitive P2X3 (homotrimeric) and P2X3/P2X2 928 
(heterotrimeric) receptor antagonists were used in these studies: AF-353 and AF-219. 929 
Although the antagonists we used have higher affinity for P2X3 homotrimeric 930 
receptors28,40,44 they cannot fully establish the relative contribution of homotrimeric 931 
P2X3 versus heterotrimeric P2X2/3 receptors. AF-353 was used in all in situ studies and 932 
was only available to us when these were performed; this drug does cross the blood 933 
brain barrier. The in vivo experiments used AF-219 as this is known not to cross the 934 
blood brain barrier. The chemical formula for AF-219 is: 935 
(amino-(4-isopropyl-2-methoxyphenyl)sulfone)-5-yl-(2,4-diaminopyrimidine-936 
5yl)ether.  The structure of AF-219 is contained in a published patent (see: 937 
http://pdfaiw.uspto.gov/.aiw?PageNum=0&docid=20150057299&IDKey=DA73323D44938 
81&). Doses used were based on IC50 data63,64. For recombinant P2X3 homotrimers the 939 
IC50 for AF-35364 and AF-219 was ~8 nM and ∼30 nM, respectively. A higher IC50 was 940 
found for P2X2/3 heterotrimeric receptors – for example 100 to 250 nM for AF-219. 941 
Note that no inhibitory effect on any non-P2X3 subunit containing receptors was 942 
noted63,64.   943 
 944 
 945 
B. Human studies 946 
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All participants gave informed consent to participate in the studies, which were 947 
approved by the Central Bristol Research Ethics Committee (REC numbers: 948 
14/SW/0054 and 12/SW/0277). 949 
 950 
Carotid body tone in hypertensive humans 951 
Small increases in circulating dopamine can decrease peripheral chemoreceptor 952 
afferent input into the brainstem65. Thus, low dose intravenous dopamine infusion (2 953 
µg/kg/min) was used to test for any tonicity from the carotid bodies. Six hypertensive 954 
humans (age 48.8±3 yr; BMI 28.6±4, three female) with an office blood pressure of 955 
>140/90 mmHg (ambulatory blood pressure: >139/91 mmHg) and on a mean of 2.83 956 
anti-hypertensive medicines were selected. Participants were given an intravenous 957 
infusion of dextrose (5%) for 5 minutes via peripheral venous access while breathing 958 
room air as a vehicle control.  After the vehicle infusion, the line was purged and the 959 
intravenous infusion of dopamine (infusion concentration: 100 μg/ml of dopamine in 960 
5% dextrose) was started for 5 minutes while breathing room air. Equivalent volumes 961 
of dextrose and dopamine were administered. Participants were blinded to the order of 962 
the infusions. This was following by a recovery period of 5 minutes while breathing 963 
room air allowing time for the dopamine to be metabolised. Respiratory volumes were 964 
measured via a respiratory flow-head connected to the expiratory port of a non-965 
rebreathing valve attached to a face mask.  Data were acquired using PowerLab and 966 
LabChart 7 software (AD Instruments) and analysed to calculate respiratory rate, tidal 967 
volume and minute ventilation using Spike2 (Cambridge Electronic Design) and 968 
MATLAB (MathWorks).   The data was analysed by GraphPad Prism 5 (GraphPad 969 
Software, Inc., USA). 970 
 971 
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Western blotting and immunocytochemical studies 972 
Human left and right carotid bodies were obtained from twelve cadavers. Briefly, 973 
carotid bifurcations were cut out, placed into cold x1 PBS and both carotid bodies were 974 
dissected and processed. The left carotid body was directly snap frozen and used for 975 
western blotting and right carotid body was immediately fixed in 4% paraformaldehyde 976 
and used for immunohistochemistry.  977 
 978 
Western blotting: The left human carotid body was crushed in liquid nitrogen with a 979 
mortar and pestle. Samples were subsequently homogenised with RIPA Lysis Buffer 980 
(Santa Cruz Biotechnology, Inc). Homogenate was centrifuged at 10,000 g for 20 981 
minutes at 4°C and the pellet was discarded. Protein concentration of the supernatant 982 
was determined by the Lowry method using the DC-protein assay kit (Bio-Rad 983 
Laboratories Ltd). Samples were mixed with loading dye (NuPage, LDS Sample Buffer 984 
4x, Life Technologies) and 20 μg of protein was used for protein electrophoresis on 4-985 
12% Bis-Tris gel (NuPage 4-12% Bis-Tris Gel, Life Technologies). The Amersham ECL 986 
Plex Western blotting system using a low-fluorescent PVDF membrane (GE Healthcare, 987 
Buckinghamshire, UK) and Alexa Fluor 488 secondary antibody (Life Technologies, UK) 988 
were used. This system enables detection and quantification with a broad dynamic 989 
range and high linearity.  After protein transfer, the membrane was blocked for 1h at 990 
room temperature with 2% Advance blocking agent (GE Healthcare). Membranes were 991 
incubated with Anti-P2X3 (APR026AN0202; 1:200 dilution) over night at 4°C. The 992 
membranes were subsequently washed with 1xPBS/0.1%Tween three times for 10 993 
minutes at room temperature. Incubation with secondary antibody Alexa Fluor 488 was 994 
carried out in the dark at room temperature. Before imaging, the membrane was 995 
thoroughly washed. Signal was detected by scanning the membrane on a fluorescent 996 
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laser scanner, Typhoon (GE Healthcare). Protein expressions were quantified using 997 
ImageQuant software (GE Healthcare). The specificity of anti-P2X3 antibody was 998 
confirmed by membrane incubation with blocking peptide (APR026AG0140, Alomone; 999 
Supplementary Fig. 10).  1000 
 1001 
Immunofluoresce: Human right carotid bodies were cut 20 μm thick on a cryostat. 1002 
Carotid body slices were incubated with 10% goat serum/0.1% Saponin (Sigma-Aldrich, 1003 
UK) for 1h at room temperature and gently agitated overnight. Primary antibody 1004 
incubation with anti-P2X3 receptor (APR026AN0202, Alomone, Israel; 1:25 dilution) 1005 
and anti-tyrosine hydroxylase (TH, F-11, sc-25269, Santa Cruz Biotechnology, Inc; 1006 
dilution 1:25) was carried out using manufacturers recommendations in 2% goat serum 1007 
over night at 4°C, overnight. Samples were then washed in 1 x PBS four times for 10 1008 
minutes at room temperature and the secondary antibody was applied for 1 hour at 1009 
room temperature. Anti-rabbit Alexa Fluor 488 was use to visualise the P2X3 receptor 1010 
and anti-mouse Alexa Fluor 594 was used to visualise tyrosine hydroxylase. Secondary 1011 
antibody incubation was followed by washing as described above and the samples were 1012 
mounted on slides using mounting medium (Vectashield, H-1000, Vector Laboratories, 1013 
Inc). Carotid bodies were examined under a Leica SP8 AOBS confocal laser scanning 1014 
microscope attached to a Leica DM I6000 inverted epifluorescence microscope and 1015 
imaging was performed using ‘hybrid’ GaAsP detectors for greater sensitivity. Images 1016 
were processed in Adobe Illustrator CS3.  1017 
 1018 
1019 
46 
 
Methods References 1020 
60. Paton, J.F.R. A working heart-brainstem preparation. J. Neurosci. Meths. 65, 63-68 1021 
(1996). 1022 
 1023 
61. Moraes, D.J. et al. Electrophysiological properties of rostral ventrolateral medulla 1024 
presympathetic neurons modulated by the respiratory network in rats. J. Neurosci. 33, 1025 
19223-19237 (2013). 1026 
 1027 
62.  Waynforth, H.B. & Flecknell, P. Experimental and Surgical Techniques in the Rat, 1028 
Second Edition, July 8, (1992). 1029 
 1030 
63. Ford, A.P. & Undem, B.J. The therapeutic promise of ATP antagonism at P2X3 1031 
receptors in respiratory and urological disorders. Front Cell Neurosci. 7, 267 (2013). 1032 
 1033 
64. Gever, J.R. et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 1034 
receptor antagonist. Br. J. Pharmacol. 160, 1387-1398 (2010).  1035 
 1036 
65. Stickland, M.K. et al. Carotid chemoreceptor modulation of blood flow during 1037 
exercise in healthy humans. J. Physiol. 589, 6219-6230 (2011).  1038 
 1039 







